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a b s t r a c t
In this study, we illustrate the utility of an agent-based simulation to inform a trial design and how this
supports outcome interpretation of randomized controlled trials (RCTs). We developed agent-based
Monte Carlo models to simulate existing landmark HIV RCTs, such as the Partners in Prevention HSV/HIV
Transmission Study. We simulated a variation of this study using valacyclovir therapy as the interven-
tion, and we used a male circumcision RCT based on the Rakai Male Circumcision Trial. Our results
indicate that a small fraction (20%) of the simulated Partners in Prevention HSV/HIV Transmission Study
realizations rejected the null hypothesis, which was no effect from the intervention. Our results also
suggest that an RCT designed to evaluate the effectiveness of a more potent drug regimen for HSV-2
suppression (valacyclovir therapy) is more likely to identify the efﬁcacy of the intervention. For the male
circumcision RCT simulation, the greater biological effect of the male circumcision yielded a major
fraction (81%) of RCT realizations’ that rejects the null hypothesis, which was no effect from the
intervention. Our study highlights how agent-based simulations synthesize individual variation in the
epidemiological context of the RCT. This methodology will be particularly useful for designing RCTs
aimed at evaluating combination prevention interventions in community-based RCTs, wherein an
intervention's effectiveness is challenging to predict.
& 2014 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
1. Introduction
HIV infection remains a major public health challenge, espe-
cially in sub-Saharan Africa [1]. Nearly 30 years of HIV research
has improved our understanding of the determinants for HIV
transmission and identiﬁed key candidate interventions to prevent
HIV infection. More than 40 randomized controlled trials (RCTs)
were designed to measure the effectiveness of interventions on
HIV incidence. These RCTs include HIV vaccines, pre-exposure
prophylaxis, antiretroviral therapy, male circumcision, and beha-
vioral interventions [2]. Regrettably, almost 90% of the RCTs failed
to demonstrate statistically signiﬁcant effectiveness against HIV
incidence [2,3]. Despite the outstanding scientiﬁc evidence sup-
porting intervention, it remains unclear why most RCTs fail to
demonstrate effectiveness [2,4–6]. However, several factors, such
as treatment adherence and retention, condom use frequency, HIV
testing, sero-disclosure, and counseling, have been proposed as
important trial components that could substantially impact RCT
results [7].
HIV transmission dynamics is a complex phenomenon. As such,
any intervention that attempts to change an aspect of these
dynamics may have unpredictable effects due to the nonlinear
interplay between factors and confounders in infection transmis-
sion dynamics [8]. This complexity may frustrate accurate estimates
for the magnitude of an effect from an intervention and, thus,
preclude an optimal trial design. This challenge is compounded by
a growing need to design RCTs and intricate multi-component
prevention intervention packages [9,10].
RCT simulation is a growing area of interest in different ﬁelds,
including HIV prevention [11–16]. In drug development, RCT simu-
lation is a well-established procedure to evaluate alternative trial
designs, test hypotheses, and interpret trial outcomes [11,15–17].
Individual variations can be determined through an agent-based
RCT simulation. The intervention's action and interaction compo-
nents can also be assessed to understand and predict the range of
possible outcomes.
The greatest beneﬁt of an agent-based RCT simulation is the
ability to directly incorporate intervention action mechanisms in
an RCT design. An RCT's particular design and outcome depend on
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the intervention's epidemiological context. As such, the interven-
tion outcome is inﬂuenced by the HIV transmission drivers in a
given population, such as behavioral factors or biological cofactors.
Therefore, an intervention's impact could differ among popula-
tions. As a formative stage of trial design, an agent-based RCT
simulation could include empirical data associated with the
infection drivers to assess an intervention's impact on a speciﬁc
population. As a result, agent-based simulations would provide
a range for the likely effectiveness of the intervention within
a speciﬁc epidemiological context; it would also estimate HIV
incidence projections for both control and intervention groups.
Hence, agent-based RCT simulation of HIV clinical trials could be
used during the formative stage of trial planning to both comple-
ment and validate conventional sample sizes and power calcula-
tions (Fig. 1). Furthermore, the trial can be conducted thousands of
times in silico under a variety of assumptions at a limited cost
compared with implementing a single trial in the ﬁeld, which is
more expensive and demanding.
In this article, we argue that agent-based HIV RCT simulation
could be an integral step in planning and designing RCTs for HIV
interventions by assisting with the multiple challenges confronted
during HIV RCT design. Furthermore, agent-based RCT simulations
could play an integral role in interpreting the trial results (Fig. 1).
Here, we show the utility of agent-based RCT simulations by
illustrating this approach using existing landmark HIV RCTs.
2. Methods
We constructed agent-based Monte Carlo models using the
MATLABs computing language version R2013a [18] to simulate
the HIV prevention RCT, the Partners in Prevention Study, which
was used to test the effectiveness of acyclovir (at 400 mg twice
daily) [19]. The Partners in Prevention Study aimed to examine the
therapeutic beneﬁts of controlling herpes simplex virus type 2
(HSV-2) reactivation and shedding on reducing HIV transmission.
Despite a signiﬁcant reduction in the mean plasma HIV viral load
and genital ulceration episodes in the treatment group, the
study demonstrated that acyclovir did not signiﬁcantly affect HIV
incidence. As a result, this ﬁeld study concluded that acyclovir
treatment in dually HIV/HSV-2-infected individuals does not
reduce the risk of HIV transmission [19]. Our study implemented
RCT simulations to examine this trial and to assess recent ﬁndings
on a potent HSV-2 suppressive therapy [20].
For comparison, we examined the drivers of success for the RCT
that assessed the effectiveness of male circumcision on reducing
HIV acquisition in Rakai, Uganda [21]. Our simulation results were
then compared with the standard power calculation results using
the original assumptions from the actual trials. In all of our
simulations, the replication unit was an individual RCT.
2.1. Scenario 1: partners in prevention study with a 0.27 log10
HIV plasma viral load reduction
As in the clinical trial [19], we generated an agent-based Monte
Carlo simulation to replicate the Partners in Prevention trial,
wherein acyclovir suppressive therapy was administered as an
intervention. The total number of HIV sero-discordant couples
simulated in each realization (which corresponded to an indivi-
dual RCT) was 3400 (1700 in the control group and 1700 in the
acyclovir intervention group).
The 2-year follow-up for the study was simulated using
monthly time steps. For each time step (equivalent to one month),
each HIV sero-discordant couple from both groups (control and
treatment) had a speciﬁc number of coital acts, c, calculated from
a normal distribution with the mean μc¼9 coital acts per month
and standard error SEc¼0.62 [22]. The number of unprotected
coital acts was estimated from a binomial distribution assuming
condom use at a 50% frequency [21,23].
The HIV-positive individual was assumed to remain in the
chronic infection stage during the entire simulation. This assump-
tion presumes that the HIV-positive partner of the stable sero-
discordant couple was infected some time before the trial began.
Thus, it was highly unlikely that the trial included HIV-positive
individuals during the acute stage of infection. The probability of
HIV transmission for each unprotected coital act without treat-
ment, pun-treat, was calculated from a normal distribution with the
mean μp¼0.0015 and SEp¼0.0001 [24,25]. For each unprotected
coital act, the simulation draws a random number from a uniform
distribution, ranging from 0 to 1, to determine whether a HIV sero-
negative individual in the control group remains uninfected or
becomes HIV-positive. If this number is smaller than pun-treat, a
transmission occurs, and the time is recorded to perform a log-
rank survival analysis.
Acyclovir reduced the HIV plasma viral load and, by exten-
sion, the probability of HIV transmission per coital act [19]. In
the treatment group, we assumed that this effect on reducing
HIV infectiousness was consonant with the empirical relation-
ship between HIV plasma viral load and HIV transmission
probability per coital act, as initially observed by Quinn and
colleagues [26].
ptreat ¼ pun treat  2:45log 10ðvlÞ ð1Þ
here, ptreat represents the probability of HIV transmission per
coital act with the intervention, and log10(vl) represents the
logarithmic (base 10) reduction in HIV plasma viral load with the
intervention. Previous RCTs conducted to measure the effect of
acyclovir 400 mg twice daily (the treatment implemented in the
Partners in Prevention trial) reported that the HIV plasma
viral load was reduced by 0.27 log10 copies/mL (i.e. log10(vl)¼
0.27) [19]. Therefore, for this simulation, ptreat¼0.0012. For
this calculation, the viral load was assumed stable during the
chronic stage of the infection [26]. After ptreat was calculated, the
same procedure described for HIV transmission per unprotected
coital act in the control group was performed to determine
whether a HIV sero-negative individual in the treatment group
remains uninfected or becomes HIV-positive. If a transmission
occurs, the time is recorded to perform a log-rank survival
analysis. Table 1 summarizes the values of the key parameters
used in this simulation. A ﬂow diagram and MATLAB code for
this simulation are included in the Supplementary material.
Fig. 1. A schematic diagram of the role for agent-based simulations on randomized controlled trial design and interpretation.
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2.2. Scenario 2: valacyclovir therapy with a 1 log10 HIV plasma viral
load reduction
For this scenario, we implemented the same simulation used
during the Partners in Prevention trial (Scenario 1). For this
scenario, however, we used valacyclovir as the suppressive
therapy. Recent ﬁndings on this potent HSV-2 suppressive therapy
in a randomized crossover trial indicated a 1 log10 plasma viral
load reduction [20]. Therefore, for this scenario, ptreat¼0.00061.
2.3. Scenario 3: male circumcision
2.3.1. Agent-based sexual network module
To simulate a male circumcision RCT as conducted in Rakai,
Uganda [21], we constructed an agent-based Monte Carlo simula-
tion based on a previous model [27]. The model consisted of a
stochastic agent-based sexual network model in which partner-
ship acquisition and dynamic processes were simulated.
In the model, equal numbers of male individuals were allocated
to the control and treatment groups (2500 in each group, as
reported in the Rakai Male Circumcision trial [21]) and assigned a
node degree (maximum number of female partners per year). We
adopted a likelihood framework to estimate the annual degree
node distribution using data from “The Malawi Social Network
Project,”which is a study on sexual networks in Malawi conducted
by the University of Pennsylvania Population Study Center [28].
For males, the reported number of sexual partners follows a
gamma distribution:
f ðnÞ ¼ nk1 e
n=θ
ΓðkÞθk
; ð2Þ
where the annual degree distribution is deﬁned as the frequency
of node degrees n in the network with the shape parameter k¼1.9
and scale parameter θ¼1.1, which were calculated from the
Malawi Social Network Project data [27,28].
We allowed two types of relationships: casual relationships
that were assumed to last 6 months on an average [27] and
marriages (long-term relationships) that were assumed to last the
entire RCT study period (24 months). Partnership formation occurs
in two steps. First, marriages are generated until reaching the
assumed percentage of marriages in the population (50%) [27].
Second, casual partnerships are then formed with the remaining
available individuals (married or single) according to the node
degree of each male individual. To introduce dynamics into
the network, these casual partnerships were allowed to end and
re-form each month.
2.3.2. Epidemiological module
HIV prevalence in the female population was assumed at
15% [29]. The HIV sero-status of each female connected with a
male in the trial was randomly assigned with a 15% probability
of being HIV-positive. We did not include male to female trans-
mission in the simulation, and we only simulated female to male
transmission. HIV incidence in females was not considered. Thus, if
a female was uninfected, she remained uninfected during the
duration of the connection with her partner. The 2-year follow-up
of the study was simulated in monthly time steps [21]. For each
time step (month), each male from both groups (control and
treatment) had a speciﬁc number of coital acts with each female
partner calculated from a normal distribution with the same
parameters (μc and SEc) used in the Partners in Prevention trial
simulation (Scenario 1).
Because each male can have more than one sexual partner, the
model calculated a number of coital acts per partnership per
month, which was assumed to be a function of the number of
partnerships for each individual. This function was deﬁned as
cn¼cN0.75 [27], where c is the number of coital acts per month
estimated in the previous step, and N is the number of partner-
ships for an individual in a speciﬁc month. This function repre-
sents individuals with multiple partnerships and more coital acts
but maintains a realistic assessment of the number of coital acts
each month.
The number of unprotected coital acts was estimated from a
binomial distribution, assuming a 50% condom use frequency,
which was also assumed in the Partners in Prevention trial
simulation (Scenario 1). If a female partner of an individual in
the control group is HIV infected, the HIV transmission process
was then simulated as described for the Partners in Prevention
trial simulation with the same probability of HIV transmission,
pun-treat, (Scenario 1). For individuals in the intervention group,
we assumed that male circumcision decreases the risk of HIV
acquisition by 60% [21,23,30,31]. Therefore, the probability of HIV
transmission per unprotected coital act for individuals in the
intervention group was pun-treat¼0.0006.
The same procedure described in the Partners in Prevention
trial simulation for HIV transmission per unprotected coital act
was implemented to determine whether the HIV sero-negative
male remains uninfected or becomes HIV-positive. If a transmis-
sion occurs, the time is recorded to perform a log-rank survival
Table 1
Key parameters used in the randomized controlled trial simulations.
Parameter Value Reference
Follow-up time 24 months [19,21]
Average number of coital acts per month 9 (95% CI 7.8–10.2) [22]
Percentage of unprotected sexual contacts per month 50% [21,23]
Number of individuals in Scenarios 1 and 2 [19]
Control group 1700
Intervention group 1700
Number of individuals Scenario 3 [21]
Control group 2500
Intervention group 2500
Probability of HIV transmission per unprotected coital act in the control group 0.0015 (95% CI 0.0013–0.0017) [24,25]
Probability of HIV transmission per unprotected coital act in the intervention group
Scenario 1 0.0012 (95% CI 0.0009–0.0014) Estimated
Scenario 2 0.00061 (95% CI 0.00041–0.00081) Estimated
Scenario 3 0.0006 (95% CI 0.004–0.008) Estimated
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analysis. Table 1 summarizes the values of the key parameters
used in this simulation. A ﬂow diagram and the MATLAB code for
this simulation are included in the Supplementary material.
2.4. Standard power calculations
Using simple power calculations with the software OpenEpi [32],
we estimated the power of the trials (the Partners in Prevention study
and Rakai male circumcision trial) to detect the statistically signiﬁcant
effectiveness of the intervention. These calculations required the input
of the sample size in the control and intervention group as well as the
percentage of individuals with outcome (HIV infection) in each group.
The parameter assumptions for these calculations were derived from
the actual trials; therefore, the Partners in Prevention study sample
size was 1700 individuals in each group. Likewise, the assumed
percentages of individuals infected with HIV during the trial were
4% and 2% in the control and intervention groups, respectively. For the
Rakai male circumcision trial, the assumed sample size was 2500 in
each group, and the percentages of individuals infected with HIV
during the trial were 2.4% and 1.2% in the control and intervention
groups, respectively. We used αo0.05 to estimate the power of both
trials.
2.5. Measure of effectiveness
To measure the intervention's effectiveness for each scenario, we
performed a log-rank survival analysis for each trial realization and its
corresponding relative risk (RR) estimation. The power of the RCT to
yield a statistically signiﬁcant result was then determined as the
fraction of realizations that reject the null hypothesis (αo0.05) [33].
The results reported in this study are based on 1000 realizations from
the models for each trial.
We also assessed the effect of the number of unprotected coital
exposures (which is affected by the number of coital acts during the
trial and condom use frequency) on the RR estimate for an RCT by
varying the number of unprotected coital exposures from ﬁve to 200
for both the acyclovir (Scenario 1) and male circumcision (Scenario 3)
interventions as described above.
3. Results
Table 2 summarizes the main results from all simulations.
3.1. Scenario 1: partners in prevention study with a 0.27 log10 HIV
plasma viral load reduction
In this scenario, the mean number of HIV sero-conversions was
47 in the intervention group and 60 in the control group (Fig. 2A),
which yielded the mean RR 0.80 (95% CI: 0.55–1.17), where the CI
represents the upper and lower bound means estimated from
1000 realizations. The log-rank test indicates that 20% of the RCT
realizations reject the null hypothesis, which has no effect from
the intervention. The RR distribution (Fig. 2B) showed a wide
variation in RR outcomes across the 1000 realizations with the RR
point estimates ranging from 0.44 to 1.52.
3.2. Scenario 2: valacyclovir therapy with a 1 log10 HIV plasma viral
load reduction
In this scenario, the mean number of HIV sero-conversions was
24 in the intervention group and 60 in the control group (Fig. 2C),
which yielded the mean RR 0.40 (95% CI: 0.26–0.65). The log-rank
test indicates that 96% of the RCT realizations reject the null
hypothesis, which was no effect from the intervention. Fig. 2D
illustrates the RR distribution across the 1000 realizations with the
RR point estimates ranging from 0.18 to 0.88.
3.3. Scenario 3: male circumcision
In this scenario, the mean number of HIV sero-conversions was
15 in the male circumcision group and 35 in the control group
(Fig. 2E), which yielded the mean RR 0.44 (95% CI: 0.24–0.80).
The log-rank test indicates that 81% of the RCT realizations reject
the null hypothesis, which has no effect from the intervention.
Fig. 2F illustrates the RR distribution across the 1000 realizations
with RR point estimates ranging from 0.02 to 1.11.
3.4. Standard power calculations
The simple power calculation results indicate that the Partners
in Prevention study had 93% power to detect the statistically
signiﬁcant effectiveness of the intervention compared with 20%
from our simulations. Likewise, the Rakai male circumcision trial
had 89% power to detect the statistically signiﬁcant effectiveness
of the intervention compared with 81% from our simulations.
3.5. The effect of the number of unprotected coital exposures on the
relative risk estimates
We explored the effect of the number of unprotected coital
exposures on the RR by varying the number of unprotected
exposures from ﬁve to 200 for the total duration of the follow-
up. As expected, the results indicate that few unprotected coital
acts per partnership during the trial yields a broad CI. It also
indicates that, as the number of unprotected coital acts increases,
the CI decreases (Fig. 3). Thus, the CI of the effectiveness measure
strongly depends on the number of unprotected coital acts in
the trial.
Table 2
Summary of the results from the randomized controlled trial simulations of the different scenarios.
Result Scenario 1 Scenario 2 Scenario 3
Mean HIV incidence rate per 100 person-year
Control group 1.76 1.76 0.70
Intervention group 1.38 0.71 0.30
Percentage of simulations with statistically signiﬁcant results
Log-rank test 20% 96% 81%
Relative risk (RR) estimation
RR 0.80 0.40 0.44
95% CIa 0.55–1.17 0.26–0.65 0.24–0.80
a The CI represents the means of the upper and lower bounds estimated from each of the 1000 realizations.
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4. Discussion
This study illustrates the value of agent-based HIV clinical trial
simulations to inform trial design. Using prior knowledge of the
clinical trial's epidemiological context, the agent-based RCT simu-
lation can provide informed input for RCT statistical designs.
Furthermore, agent-based RCT simulation can play an integral role
in interpreting the trial outcome (Fig. 1), as discussed below.
We assessed the utility of agent-based RCT simulation by
examining the difﬁculty in measuring effectiveness even in the
fairly simple epidemiologic system with HIV sero-discordant
couples, wherein the acyclovir therapy interventionwas evaluated.
Our results show that only 20% of the realizations for this trial
reject the null hypothesis, which was no effect from the interven-
tion. Furthermore, assuming that parameter assumptions are met
(such as the effectiveness of the intervention, the number of
sexual contacts, the probability of HIV transmission per sexual
contact, and condom use, among others), the actual Partners in
Prevention Study results with the RR 0.92 (95% CI: 0.60–1.41) [19]
was highly probable based on the RR distribution derived from this
trial simulation (0.44–1.52) (Fig. 2B). This result substantially
differs from the 93% power estimated from simple power calcula-
tions using parameter assumptions derived from the actual trial.
On the other hand, when the estimates for the effectiveness of the
intervention and HIV incidence projections derived from our
agent-based simulations were used with a standard sample size
and power calculations, the results were consonant with the
estimated power from our agent-based simulations.
We show that the trial should have included a minimum
number of unprotected coital acts to observe a statistically
signiﬁcant effect from the intervention. As mentioned previously,
the number of unprotected coital acts could be affected by either
the total number of coital acts during the trial or condom use
frequency. With the parameter values assumed in this study, it was
impossible to detect a signiﬁcant effect on HIV transmission with
fewer than 100 unprotected coital acts (Fig. 3A). We assumed a
high rate of condom use (50%) [21,23], which also contributed to
the low incidence in the control group in this simulation (1.76 per
100 person-year). However, the actual Partners in Prevention trial
reported a higher condom use rate, exceeding 90% [34]. Using this
number, we estimated less than 20 unprotected coital acts per
couple for the entire study duration. Our analysis indicates
that this number of infection exposures is too low to detect a
signiﬁcant effect from the treatment. As such, it could be a major
reason for the substantial discrepancy between the power calcu-
lated from the simple power calculations and the power estimated
from our simulations.
However, this observation should be understood neither as a
shortcoming in the design of this landmark study nor as a post-
hoc power analysis with the hindsight of the trial results. Several
unexpected factors conspired to undermine the ability of the trial
to measure the intervention's effectiveness. The high rate of
Fig. 2. The number of HIV infections and relative risk distribution for the different scenarios: (A) the Partners in Prevention HSV/HIV Transmission Study simulation
(Scenario 1) with the distribution for the number of HIV infections in the intervention (red bars) and control groups (blue bars); (B) the corresponding relative risk
distribution. (C) HIV infection distribution for valacyclovir therapy with a 1 log10 HIV plasma viral load reduction (Scenario 2), and (D) its corresponding relative risk
distribution. (E) The HIV infection distribution for the Rakai male circumcision trial simulation (Scenario 3), and (F) its corresponding relative risk distribution. (For
interpretation of the references to color in this ﬁgure, the reader is referred to the web version of this article.)
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condom use reduced the expected event rates and, thus, prevented
sufﬁcient infection exposure. The lack of a signiﬁcant effect from
the trial was due to its success in HIV testing, sero-disclosure, and
counseling. This result highlights how standard care and ethical
issues are inescapable challenges that can impact clinical trial
results. It can potentially reduce the expected HIV incidence in the
control group, thereby compromising the study's ability to detect
a signiﬁcant effectiveness from the intervention.
If the acyclovir 400 mg twice daily regimen evaluated in the
Partners in Prevention Study is replaced by an acyclovir 1.5 g twice
daily regimen [20], the trial would likely measure a signiﬁcant
effect from the intervention. Ninety-six percent of the realizations
reject the null hypothesis, which was no effect from the interven-
tion, and indicate an approximately 60% effectiveness (Scenario 3;
Fig. 2E). This result is comparable to the biological effectiveness of
male circumcision [21,23,30,31].
Due to the magnitude of the effect from male circumcision and
the intermediate percentage of condom use (49%) in the Rakai
Male Circumcision trial [21], a signiﬁcant effect was observed for
the intervention in the male circumcision trial even with a small
number of unprotected coital acts (Fig. 3B). Our simulation-based
0.44 RR mean (95% CI: 0.24–0.80) corresponds with the Rakai
study estimates (Kaplan–Meier risk ratio 0.40; 95% CI 0.23–0.70)
[21]. Likewise, the power estimated from simple power calcula-
tions is consistent with the power estimated from our simulations.
These results suggest that it would be highly unlikely for the male
circumcision trials to fail in measuring a signiﬁcant effect from the
intervention.
Our simulations highlight how even in a relatively simple
epidemiological context (such as observed in the HIV sero-
discordant couples), predicting the outcome of an intervention
RCT is not straightforward. Therefore, agent-based RCT simulation
would become an important step in designing RCTs aimed at
evaluating prevention interventions, such as vaginal and rectal
microbicides, in which a complex array of factors and nonlinear
interactions may impact the trial outcome [35]. For instance, the
observed effectiveness of microbicides at reducing HIV infection
results from a complex interplay of several components, such as
sexual behavior, adherence, and the microbicide's effectiveness [36].
Consequently, the potential effectiveness of a microbicide in redu-
cing HIV transmission could differ among populations with different
risk behavioral patterns. Therefore, the agent-based RCT simulation
might aid in sample size and power calculations by integrating
these behavioral characteristics for the target population.
Additionally, epidemiological evidence and outcomes from
previous HIV intervention RCTs demonstrate the absence of a
single “magic bullet” to control infection spreading. As a result, the
HIV prevention community is currently moving towards testing
multi-component HIV prevention interventions in community-
based RCTs, which include evaluating universal home-based test-
ing, antiretroviral therapy, and male circumcision [9,37]. Because
each intervention component might require a different time scale
for the full effect, it would be necessary to explore the develop-
ment of an intervention package's impact over time using an
agent-based RCT simulation. Thus, agent-based HIV clinical trial
RCT simulation could become an important tool to account for
nonlinear interactions between the combination package inter-
vention components as well as between the intervention and
epidemiological context.
Thus, agent-based RCT simulations would be particularly useful
for designing community-based RCTs. Far from being a direct
consequence of the intervention at the individual level, the effect
measured for community-based RCTs results from an interplay of
the intervention and infection characteristics at the population
level. In community-based trials, the level of indirect impact
(herd effect) caused by decreasing HIV prevalence in the commu-
nity is difﬁcult to characterize. Moreover, agent-based simulations
could account for other indirect effects that affect HIV incidence
over time, thus compromising the power of the study; examples
include the standard clinical care offered to the control group and
the intervention scale-up in the intervention group [14,37].
Agent-based RCT simulations could also be implemented to
inform trial development, monitor trial progress, and guide
decision-making at latter stages of the trial. For instance, if the
trial fails to measure the intervention's efﬁcacy after the trial has
been conducted for a certain period of time, agent-based simula-
tions using data derived from the actual trial could better inform
certain decisions (such as halting the trial). This method could
guide potential improvements to performing the intervention.
Subsequently, the likelihood of reaching the desired intervention
effectiveness during the remainder of the trial will have increased.
However, the value of agent-based simulations during these trial
stages depends on accessibility of data from the actual trial. As is
often the case with these types of studies, the data are not easily
available due to safety and data conﬁdentiality.
In this modeling exercise, we constructed simple models to
illustrate the practicality of agent-based computer simulations in
designing and implementing of HIV prevention RCTs. Several study
limitations and modeling assumptions may have affected our
results. First, we did not include important factors that could
affect the outcome for a RCT, such as treatment adherence and
retention. Furthermore, other sources of individual and epidemio-
logical heterogeneity were not included, such as age-related
characteristics (e.g., number of sexual partners, number of coital
acts per partnership, and condom use), different probabilities of
HIV transmission according to the infection stage, variability in
screening frequency, and co-infections. More realistic and complex
agent-based network simulations including these factors would
be more appropriate for designing new HIV prevention RCTs,
particularly those intended to evaluate a combination of interven-
tions to prevent HIV transmission.
Fig. 3. Effect of the number of unprotected coital acts on the relative risk
estimation. The red line represents the relative risk trends, and the blue lines
represent the corresponding conﬁdence interval for (A), assuming a 0.27 log10 HIV
plasma viral load reduction (the 400 mg twice daily acyclovir regimen), and
(B) male circumcision.(For interpretation of the references to color in this ﬁgure,
the reader is referred to the web version of this article.)
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However, the level of complexity for an agent-based RCT
simulation should be carefully considered, and it should not exceed
the necessary level of complexity to meet the objectives of the
analysis. Parameter assumptions are an inherent feature of agent-
based simulations. Certain assumptions could be more deﬁnite than
others depending on the degree to which the assumptions are
justiﬁed by epidemiological and behavioral data, among other
considerations. Therefore, sensitivity analyses would serve as a
fundamental stage for agent-based HIV clinical trial simulations to
evaluate the impact of these assumptions on the simulation results.
These sensitivity analyses could also assess the impact of variation
in important programmatic and implementation components, such
as demographic processes, the scale-up speed, patient drop-out,
and intervention adherence as well as retention.
Despite these limitations, our study highlights how agent-based
simulations of HIV intervention RCTs could provide powerful tools
for optimizing the RCT designs. Conventional statistical methods for
RCT design may not be sufﬁcient to discern either the spectrum or
complexity of potential outcomes. This is particularly true in HIV
prevention research, where a complex array of factors may impact
the trial results. Such factors include expected biological effective-
ness, intervention adherence, coital act frequency, condom use
frequency, partnership formation and the sexual network structure.
However, it must be emphasized that agent-based RCT simula-
tion using mathematical modeling is neither an alternative to nor
a replacement for statistical methods in a study design. Rather, it is
a methodological tool that could be implemented prior to statis-
tical design to realistically estimate the potential size of the effect
(Fig. 1). It could also be a methodological tool implemented
following an RCT to aid in interpreting the results (Fig. 1).
5. Conclusions
In sum, our study highlights how agent-based simulations of
HIV intervention RCTs might synthesize the intervention's
mechanistic process and epidemiological context. It could also
predict and evaluate the range of outcomes in a trial, considering
uncertainties such as the trial subjects' sexual behavior. In a
climate of ﬁnancial challenges, this approach could enhance the
likelihood of a trial's success and would also aid in avoiding
evidence that obscures the effectiveness of potential interventions.
6. Summary
6.1. Background
The majority of HIV prevention RCTs fail to measure statistically
signiﬁcant efﬁcacy for the tested interventions despite a solid
epidemiological foundation for the intervention concept. In this
study, we discuss implementing agent-based HIV RCTs simulations
as an integral step in planning, designing, and interpreting RCTs
for HIV interventions. This tool would complement conventional
statistical methods in designing trials by estimating the likely
magnitude of the effect for a speciﬁc epidemiological context. As
such, it provides informed input for power and sample size
calculations. Likewise, HIV RCT simulations would play an integral
role in interpreting the trial outcome. We show the utility of HIV
RCT simulations by illustrating this tool for existing landmark
HIV RCTs.
6.2. Methods
We developed agent-based Monte-Carlo models to simulate
the Partners in Prevention HSV/HIV Transmission Study, variations
of this study, and the Rakai Male Circumcision Trial. The models
were parameterized using data from these RCTs. Each trial was
simulated 1000 times, and statistical methods were implemented
to assess the outcome of each trial simulation.
6.3. Results
Our analyses indicate that the Partners in Prevention Study had
a low (20%) likelihood of rejecting the null hypothesis, which was
no effect from the intervention. In contrast, most (96%) of the
RCT realizations from a simulation with a different and more
potent drug regimen for HSV-2 suppression (valacyclovir therapy)
rejected the null hypothesis. For the male circumcision RCT
simulation, the greater magnitude of the biological effect from
male circumcision resulted in a substantial number (81%) of RCT
realizations that rejected the null hypothesis.
6.4. Conclusion
Our study demonstrates the explanatory power of agent-based
simulations of RCTs. It also shows how such simulations can
inﬂuence HIV prevention research. A simulation approach would
enhance the likelihood of a trial's success and aid in avoiding
evidence that obscures the effectiveness of potential interventions.
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